http://biotuesdays.com/2016/08/30/bioasis-in-peer-reviewed-pharmaceutical-research/

Bioasis in peer-reviewed Pharmaceutical Research

August 30, 2016 by Shane Matte · Leave a Comment

Bioasis Technologies (OTCQX:BIOAF; TSX-V:BTI) has published a peer-reviewed scientific paper in Pharmaceutical Research, an official journal of the American Association of Pharmaceutical Scientists, detailing results of an in vivo study of the treatment of metastatic HER2-plus breast cancer brain tumors in an animal model using BT2111, its Transcend conjugate.

The results detailed in the paper are from studies performed under the direction of Dr. Paul Lockman at Texas Tech University Health Sciences Center School of Pharmacy.

In the study it was shown that the BT2111 reduced the number of metastatic human HER2+ breast cancer tumors in the brains of test animals by 68%, compared with control animals. Tumors that remained after treatment were 57% to 60% smaller than those in the control animals.

The authors of the paper said that the results presented in this study provide evidence that BT2111 has efficacy in treating brain metastasis in preclinical models and validates the role hMTf has as a vector (Transcend vector platform) for the transport of antibodies across the blood-brain barrier.

“This study has shown that Transcend can deliver Herceptin, a chemotherapeutic used to treat HER2-positive breast cancer, in sufficient quantity to the brain to significantly reduce the number of HER2-positive metastatic brain tumors. The ability to more effectively permeate both the blood-brain and the blood-tumor barrier opens the door for the creation of new drugs designed to treat a wide variety of neurological diseases and disorders,” the authors added.